LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024.
Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event atwww.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320 (US/Canada) or 973-528-0002 (International), passcode 903508, approximately ten to five minutes prior to the start time.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology and include the T2Dx®Instrument, the T2Bacteria®Panel, the T2Candida®Panel, the T2Resistance®Panel, and the T2BiothreatTM Panel. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the T2LymeTM Panel, and the expended T2Candida Panel to add the detection ofCandida auris. For more information, please visitwww.t2biosystems.com.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
